Skip to main content

Status message

You must login before you can repin.


The honest response is to stop designing trials around inert placebos and build more credible control conditions. That means active comparators like low-dose stimulants, niacin, or sub-therapeutic microdoses, combined with centralized raters who are blinded to the patient's dosing experience and kept structurally separate from the therapeutic team. https://salienceclinical.com/